Small-molecule prodrug
approaches that can activate cancer therapeutics
selectively in tumors are urgently needed. Here, we developed the
first antitumor prodrugs designed for activation by thiol-manifold
oxidoreductases, targeting the thioredoxin (Trx) system. The Trx system
is a critical cellular redox axis that is tightly linked to dysregulated
redox/metabolic states in cancer, yet it cannot be addressed by current
bioreductive prodrugs, which mainly cluster around oxidized nitrogen
species. We instead harnessed Trx/TrxR-specific artificial dichalcogenides
to gate the bioactivity of 10 “off-to-on” reduction-activated
duocarmycin prodrugs. The prodrugs were tested for cell-free and cellular
reductase-dependent activity in 177 cell lines, establishing broad
trends for redox-based cellular bioactivity of the dichalcogenides.
They were well tolerated in vivo in mice, indicating
low systemic release of their duocarmycin cargo, and in vivo anti-tumor efficacy trials in mouse models of breast and pancreatic
cancer gave promising indications of effective tumoral drug release,
presumably by in situ bioreductive activation. This
work therefore presents a chemically novel class of bioreductive prodrugs
against a previously unaddressed reductase chemotype, validates its
ability to access in vivo-compatible small-molecule
prodrugs even of potently cumulative toxins, and so introduces carefully
tuned dichalcogenides as a platform strategy for specific bioreduction-based
release.